Biogen Alzheimer’s Drug Slows Decline, Lowers Tau
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Biogen advanced its experimental Alzheimer’s drug diranersen into Phase 3 development after mid-stage trial data showed it slowed cognitive decline at rates comparable to approved therapies
- Diranersen improved patient performance across multiple tests compared to placebo, with different doses producing measurable benefits in the Phase 2 trial
- Tau protein levels were reduced by diranersen, demonstrating the drug’s ability to impact a key biomarker linked to toxic brain tangles and memory loss in Alzheimer’s
- Alzheimer’s specialists observed that the drug appeared to affect disease progression, citing consistent improvements across cognitive assessments in treated patients
- The Phase 2 results bolstered Biogen’s case for moving to Phase 3, though experts emphasized that definitive conclusions await larger pivotal trial data
Why it matters: The drug’s comparable performance to approved therapies—combined with its effect on tau, a core Alzheimer’s pathology—means Biogen could challenge the bar for clinical meaningfulness in a field where modest benefits have sparked controversy. If Phase 3 confirms these results, regulators, insurers, and clinicians may face renewed pressure to define what level of cognitive slowing justifies approval and coverage.
